You are here: Industry Insights > UCB

News List

UCB to invest £1 billion into UK R&D pharmafile
December 10, 2018
The Brussels-based multinational UCB will invest £1 billion into UK research and development, according to the government’s Life Sciences Sector Deal, which details public and private sector
UCB to invest £1 billion into UK R&D pharmafile
December 07, 2018
The Brussels-based multinational UCB will invest £1 billion into UK research and development, according to the government’s Life Sciences Sector Deal, which details public and private sector investments into Britain’s life sciences industry.
UCB to invest £1bn into UK under life sciences sector deal pharmatimes
December 07, 2018
The government has published the second Life Sciences Sector Deal, detailing both public and private sector investments into the sector, including a £1 billion investment in UK research and development (R&D) by UCB.
UCB to invest £1bn in the UK Life Sciences Sector Deal pharmaceutical-technology
December 06, 2018
Belgian biopharmaceutical company UCB has agreed to invest approximately £1bn ($1.27bn) as part of a collaboration between the UK government and life sciences industry intended to support healthcare innovation in the country......
UCB’s new app uses voice AI to help Parkinson’s patients fiercepharma
December 05, 2018
April would like to talk—to Parkinson’s patients and caregivers. "She" is the virtual health assistant on UCB’s new mobile app built specifically for Parkinson’s disease.
Amgen, UCB Announce FDA to Review Evenity americanpharmaceuticalreview
December 04, 2018
Amgen and UCB announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data ......
Enable Injections Partners with UCB and Apellis Pharmaceuticals contractpharma
November 14, 2018
Enable Injections Partners with UCB and Apellis Pharmaceuticals
UCB and Biogen's lupus drug falls short at Phase 2b pharmafile
October 25, 2018
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet its primary endpoint in the treatment...
UCB brings promising plaque psoriasis data to EADV 2018 pharmafile
September 20, 2018
UCB has joined in on the wave of new psoriasis data emerging from the European Academy of Dermatology and Venereology (EADV) Congress 2018...
UCB and PharmaMar breach ABPI Code of Practice pharmatimes
July 17, 2018
UCB and PharmaMar have been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s Code of Practice.

Previous page 1 2 3 4 5 6 Next page